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INTRODUCTION
In severe acute pancreatitis the inflammation of the
pancreas does not remain in the pancreas, local field
and circumference. Due to a reaction of pancreatic
enzymes and cytokines, which spread throughout the
whole body, the inflammation affects the whole body.
Then, neutral proteinase and active oxygen are dis-
charged, with the activation of neutrophils. As a result,
from the early crisis stage severe acute pancreatitis
combines with multiple organ failure (MOF) and dis-
seminated intravascular coagulation syndrome (DIC)
(1). Therefore, a causal therapy for the pancreas local
field and a general treatment for MOF and DIC are
required.
Gabexate mesilate (FOY-007) is a protease inhibitor
with a broad spectrum inhibiting not only trypsin and
kallikrein, but also plasmin, thrombin, factorXa, elastase,
complement 1 (C1), esterase and phospholipaseA2 (2).
Prophylactic application of FOY-007or Camostat me-
silate (FOY-305) showed some beneficial effect in CDE-
induced pancreatitis (3, 4), cerulein-induced panceratitis
(5) and sodium taurocholate-induced panceratitis (3).
The therapeutic effect of FOY-007 in acute panceratitis
has been ascribed to its inhibition of pancreatic enzyme
activity, like trypsin, thus preventing autodigestion (5).
The FOY-007 infusionmethod is generally an intra-
venous infusion method. In addition, there is the in-
traduodenal infusionmethod of Takasugi et al. (6) and
the intraductal administration method of Wakayama
et al .(7). Both studies reported that the spreadof acute
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pancreatitis was prevented. However, there have been
very few experimental reports on the intraarterial in-
fusion method.
The purpose of the present experimentwas to assess
the therapeutic effect of continuous arterial infusion
of FOY-007 in a lethal model of acute necrotizing pan-
creatitis in dogs.
MATERIALS AND METHODS
Animals
Adult mongrel dogs of both sexes, weighing between
10 and 20kg, were used throughout the study. They
were kept under standard conditions (12 : 12 h light-
dark cycles), and fed an ordinary laboratory diet (Clea,
Japan) and water. All experiments were performed
in animals after 12h fasting with free access to water.
Canulation to the celiac artery and induction of acute
necrotizing pancreatitis
All procedures were performed under sterile con-
ditions. Adultmongrel dogswere anesthetized by intra-
venous injection of pentobarbital sodium (50mg/kg,
Abott Laboratory, North Chicago,Ⅲ.,USA) followed
by endotracheal intubation. Theyweremaintained on
controlled breathed 30% oxygen. The right femoral
vein was cannulated with a 16-gauge intravenous hy-
peralimentation catheter to infuse a lactated Ringer’s
solution at a rate of 10 ml/kg/h. The right femoral
artery was cannulated with a 20-gauge Teflon catheter
to monitor arterial blood pressure for blood sampling.
After an upper abdominal median incision, the left gas-
tric artery was exposed and cut downwards, and a 3
Fr. Polyethylene catheter (ID, 1.0mm ; Atom, Japan)
was inserted in the retrogradation from the distance
edge. The tip of the catheter was placed at the celiac
artery. After Indigocarmine was injected from the
catheter, we confirmed that the left and right lobes of
the pancreas were stained. Acute necrotizing pancrea-
titis was induced by the injection of 10% sodium tauro-
cholate (1.0ml/kg for 5 min) to the main pancreatic
duct.
Experimental protocol
Experimental animals were divided into three groups.
Group A (non-treatment group, n=6) : No drugswere
given during the experiment. GroupB : FOY-007 was
given intravenously for 6 hrs after the induction of
pancreatitis (5mg/kg/hr, n=9). GroupC: FOY-007was
given via the celiac artery for 6 hrs after the induction
of pancreatitis (5mg/kg/hr, n=9).Theuseof anesthesia
during experimental procedures was consistent with
the National Institutes of Health guidelines for the care
and use of laboratory animals.
Hemodynamic parameters
A pressure transducer, Uniflow (Baxter Co.), was
connected to the needle of a 20 gauge, which was in-
serted intraoperatively into the right femoral artery
of each experimental animal. Using this transducer,
the systolic arterial pressure (SAP, mmHg) and dia-
stolic arterial pressure (DAP,mmHg)were measured
in all experimental animals 6 hours after the operation.
We then calculated the mean arterial pressure (MAP,
mmHg) in each animal. MAP was derived from the
equation DAP＋1/3×(SAP-DAP).
Serum and ascites samples
Before, 1, 2, 4, and 6h after the injection of 10% so-
dium taurocholate, bloodwas quickly withdrawn from
the right femoral artery to measure amylase, lipase,
alanine aminotransferase (ALT), lactic dehydrogenase
(LDH), calcium (Ca), blood urea nitrogen (BUN) and
creatine (Cr). Also, 1, 2, 4, and 6h after the injection of
10% sodium taurocholate, dogs were relaparotomized
and ascites were quickly withdrawn from the Douglas
pouch to measure amylase and lipase. Serum and
ascites samples were stored at -80℃. Amylase was
measured by enzymatic assay using an amylase assay
kit (Pureauto amy-c, Daiichi Pure Chemicals CO. LTD),
and lipase wasmeasured by a spectrophotometric assay
using a lipase kit (Liquitech Lipase color, Roche Diag-
nostic). ALT, LDH, CawasmeasuredusingALT, LDH
and Ca assay kits (L-typeWakoALT, L-typeWakoLDH,
and Calcium E-H test Wako, respectively ;Wako Phar-
maceutical Co., Ltd.). Serum BUN levels were meas-
ured, usingQuick AutoⅡBUN (Sino Test, Co.) , while
serum creatinine levels were measured using an L-
type Wako Creatinine F (Wako Pharmaceutical Co.,
Ltd.).
Histological examination
Dogs were sacrificed 6hrs after an injection of 10%
sodium taurocholate. The pancreas was removed and
subsequently fixed with 10% formaldehyde. A slice was
collected from the left lobe and from themain pancre-
atic duct bifurcation to a 2cm interval, and hematoxylin-
eosin staining was carried out on a total of 5 slices for
histological examination. The ratio of pancreatic ne-
crosis was measuredwith the image analysis software
NIH image 1.61(NIH, Bethesda, Md., andUSA). The
area of pancreas substance was calculated for every
slice, as well as the area of the parts that showed clear
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necrosis. The area ratio (the pancreatic necrosis area/
pancreas substance area), andmean value of pancreatic
necrosis area/pancreas substance area ratio for all slices
were also calculated. The mean values of each group
were compared and examined.
FOY-007 levels in pancreas specimens
The pancreas was frozen in 3 dogs from group B
and C in liquid nitrogen prior to sacrifice. Pancreatic
tissue weighing 0.2g was accurately collected from
the left, center, and right end of the left lobe. The FOY-
007 concentrations were determined (ONO Pharma-
ceutical Co., Ltd). The FOY-007R concentrations were
examined in terms of the mean value of each group.
Statistical analysis
Statistical analysis was performed using one-way
analysis of variance and the Student’s t test. Each result
was expressed as the mean±SE. Statistical signifi-
cance was set at P<0.05.
RESULTS
Hemodynamic parameters
Before the experiment in group A, the systolic ar-
terial pressurewas183±22mmHg.However, the systolic
arterial pressure 6 hours after the operation was sig-
nificantly lower compared to that before theexperiment.
In group B, the systolic arterial pressure tended to be
lower postoperatively : at 6 hours it was significantly
low. In groupC, 2 hours postoperatively it showed that
a low value, but tended increase thereafter (Table 1).
The mean arterial pressure showed the change was
equal to the systolic arterial pressure (Table 1).
Table 1. Hemodynamic pressure parameters in each experimental group for time after induction of pancreatitis
Parameter pre-op 1 h 2 h 4 h 6 h
SAP(mmHg)
Group A 183±22 137±40※ 131±25＊ 143±20※ 138±36※
Group B 173±53 148±34 141±29 133±32 127±33※
Group C 179±27 145±23 142±32※ 154±34 159±31
MAP(mmHg)
Group A 136±13 99±29＊ 98±21＊ 103±15※ 103±23※
Group B 125±42 115±27 111±24 102±25 96±24
Group C 132±14 115±20 111±24 118±21 121±23
Hemodynamic pressure parameters in each experimental group for time after induction of pancreatitis. Hemodynamic pressure pa-
rameters in each experimental group for time after induction of pancreatitis. Group A is the non-treatment group (n=6), Group B re-
ceived FOY-007 intravenously (n=6), Group C received FOY-007 via the celiac artery (n=6). Symbols indicate the significant difference
of blood pressure in each experimental group for time after induction of pancreatitis, compared to that of preoparation. ※(P＜0.05),
versus preoparation.＊(P＜0.01), versus preoparation. SAP , systolic arterial pressure.MAP , mean arterial pressure.
Fig 1. Serum amylase (A) and lipase (B) levels. ■, Group A
is the non-treatment group (n=6) ;

, Group B received FOY-
007 intravenously (n=6);

, Group C received FOY- 007 via the
celiac artery (n=6), respectively. Symbols indicate the significant
difference in each experimental group for time after induction
of pancreatitis, as follows :※(P<0.01), Group A versus Group B.
＊(P<0.01), Group A versus Group C. Pre-OP , preoperation.
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Serum amylase and lipase levels
In group B and C amylase level in serum was sig-
nificantly low comparedwith that in groupA at all time
points after induction of pancreatitis (Fig. 1A). In group
B and C lipase level in serum was significantly lower
compared with that in group A at all time points after
induction of pancreatitis (Fig. 1B).
Amylase and lipase levels in ascites
In group B, the amylase level in ascites was not sig-
nificantly lower compared with that in group A at all
time points after induction of pancreatitis, but in group
C it was significantly low 2, 4, and 6 hrs after induction
of pancreatitis (Fig. 2A). Only the lipase level in ascites
in group C was low compared with that in group A at
all time points after induction of pancreatitis. Especially,
it was significantly low 6 hrs after induction of pancrea-
titis (Fig. 2B).
Serum ALT, LDH and Ca levels
No significant differences in serum ALT, LDH and
Ca levels were found in any group (Fig. 3A-C).
Serum BUN and Cr levels
In group C, the BUN level was significantly low 1,
Fig 2. Amylase (A) and lipase (B) levels in ascites. ■, Group
A is the non-treatment group (n=6) ;

, Group B received FOY-
007 intravenously (n=6) ;

, Group C received FOY-007 via celiac
artery (n=6), respectively. Symbols indicate the significant differ-
ence in each experimental group for time after induction of pan-
creatitis, as follows :＊(P<0.05), Group A versus Group C.
Fig 3. Serum ALT (A) LDH (B) and Ca (C) levels.■, Group
A is the non-treatment group (n=6) ;

, Group B received FOY-
007 intravenously (n=6) ;

, Group C received FOY-007 via the
celiac artery (n=6), respectively. Pre-OP, preoperation.
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�and 2 hrs after induction of pancreatitis (Fig. 4A), but
no significant differences in serum Cr levels were
found in any group (Fig. 4B).
Histological examination of the autopsy pancreas
Falling and necrosis of the pancreatic substance and
edema of the interstitial tissue were widely recognized
in group A in the autopsy histological examination
(Fig. 5A). In groupB, the edema changes in the inter-
stitial tissue remained, and the necrosis rangewas de-
creased compared with that in group A (Fig. 5B). In
group C, the edema change of the interstitial tissue
remained slightly, and the necrosis rangewas slightly
lower (Fig. 5C). The extents of pancreatic parenchyma
necrosis in each group were 36.1±2.6, 25.3±7.5 and
19.5±2.3%, respectively.Especially, ingroupC the extent
of pancreatic parenchyma necrosis was significantly
lower compared with that in group A (Fig. 6).
Fig 4. SerumBUN (A) and Cr (B) levels.■, Group A is the non-
treatment group (n=6) ;

, GroupB receivedFOY-007 intravenously
(n=6) ;

, Group C received FOY-007 via the celiac artery (n=6),
respectively. Symbols indicate the significant difference in each
experimental group for time after induction of pancreatitis, as fol-
lows. ＊(P<0.05), Group A versus Group C.
Fig 5. Histological findings of experimental animals. The find-
ings of the pancreatic specimen, magnified 10 times (HE staining),
taken by autopsy. A-C shows the findings of the specimen in group
A-C.
Fig 6. The ratio of pancreatic necrosis area/pancreatic substance
area, taken by autopsy. ■, Group A is the non-treatment group
(n=6) ;

, Group B received FOY-007 intravenously (n=6) ;

,
Group C received FOY-007 via the celiac artery (n=6), respectively.
Symbols indicate the significant difference in each experimental
group 6 hours after induction of pancreatitis, as follows :＊(P<
0.05), Group A versus Group C.
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FOY-007 levels in the pancreas specimens
FOY-007 levels in the pancreas specimens in group
B were 234.6±50.4 ng/g, and 7562.1±2620.9 ng/g
in group C. FOY-007 levels in the pancreas specimens
in groupC exceeded those in groupBby32 times (Fig.
7A). In comparison with the individual part of the
pancreas, in groupB, FOY-007 levels in the pancreatic
head were 302.9±125.7ng/g, 234.7±8.7ng/g in the
pancreatic body, and 166.1±99.5ng/g in the pancreatic
tail. In group C, FOY-007levels in the pancreatic head
were 3528.6±1927.9ng/g, 10735.7±3326.4ng/g in the
pancreatic body, and 8421.9±7356.0ng/g in the pan-
creatic tail. In the pancreatic body, FOY-007 levels in
group C were significantly higher than those in group
B (Fig. 7B).
DISCUSSION
In severe acute pancreatitis, the inflammation of the
pancreas local field spreads to not only the pancreas
and pancreas circumference from the early stage, but
also to the wholebody. As a result, the death rate is
high, despite severe acute pancreatitis being a benign
disease, because of DIC andMOF. Itwas reported that
acute pancreatitis occurred in 45,000 people a year,
while about 4,000 people died from complications in
USA (8). In Japan, it was reported the death rate was
30% in a national investigation from 1982 to 1986, and
27% in 1996. The therapy for severe acute pancreatitis
was divided between topical treatment for the pancreas
local field whichwas the primary cause of disease, and
general treatment for impor-
tant organ failure in the early
stage, and multiple organ fail-
ure based on severe infectious
disease in the later stage.We
assumed the best way to pre-
vent deteriorationof acute pan-
creatitis was to control the in-
flammation in thepancreas lo-
cal field in theearlystage.There
fore, we examined topical pan-
creas treatment. As a result,
in the intraarterial injection
group, systolic arterial pressure
and mean arterial pressure
were lowered immediately
after the operation, and the
improvement tendency was
recognized from 2 postopera-
tive hours. At 6 postoperative
hours, it was improved without significance compared
to the preoperative value.However, in thenon-treatment
and intravenous infusion groups, it lowered imme-
diately after the operation, and the improvement ten-
dency was not observed afterwards. This suggested
that from the above result, FOY-007 continuous arte-
rial infusion therapy improved early systemic circulation
in the dynamic phase, and that it could prevent early
organ failure.
In acute pancreatitis, trypsin is activated in zymogen
granules of pancreatic acinus cells for various reasons
(9 -11). Then, many varied deactivated pancreatic
enzymes are activated by trypsin. As a result, the ac-
tivated pancreatic enzymes deviate from the zymogen
granules to interstitial tissue. This causes necrosis of
the pancreatic acinus cells, edema of the interstitial
tissue, failure of capillary and pancreatic ducts, and
hemorrhaging necrosis of the pancreas circumference
and retroperitoneum fat. In addition, the progress of
this destruction induces the activation ofmacrophages,
large cytokines, and the accumulation of neutrophils
in the target organ. As a result, neutrophils which accu-
mulate in target organ cause an organ disorder (12).
Historically, the intravenous injection of aprotinin,
a protease inhibitor for acute pancreatitis, was widely
performed. However, the effect of aprotinin was not
adequately, because in the intravenous infusion of
aprotinin, it was only slightly taken up in pancreas
(13). The molecular weight of aprotinin is high at
6,512. Therefore, the interference activity for trypsin
which combines with α 2-macroglobulin, an internal
protease inhibitor, was very weak. It did not inhibit
Fig 7. FOY-007 levels in the total pancreatic specimens (A) and part of the specimens (B).
, Group B received FOY-007 intravenously (n=3) ;

, Group C received FOY-007 via the
celiac artery (n=3), respectively. Symbols indicate the significant difference in both experimental
groups 6 hours after induction of pancreatitis, as follows :＊(P<0.05).
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thrombin, Clr or Cls. Takeda et al. pointed out in 1987
since aprotinin of sufficient quantity in intravenous
infusion did not reach to the pancreas, inflammation
of the pancreas local field could not be controlled.
The progress of pancreatitis could be suppressed by
raising the aprotinin concentration in the pancreas.
They devised continuous arterial infusion therapy
with aprotinin and reported that there was no difference
in pancreatic necrosis between the control group and
the intravenous infusion group, while pancreatic necrosis
was very slight in the intraarterial infusion group (14).
In 1990, Kadokawa et al. found that the effect of con-
tinuous arterial infusion therapy using Nafamostat
mesilate (FUT-175) had interference activity whichwas
more powerful than aprotinin, its molecular weight is
540. They reported that in the intravenous infusion
group, it insufficiently suppressed the progress of pan-
creatic necrosis, while the concentration of FUT-175 in
the pancreatic tissues in the intraarterial infusion group
was 5 times that in the intravenous infusion group. In
addition, Trypsin Like Activity in the pancreas tissues
was clearly lowered, so the progress of pancreatic ne-
crosis was also suppressed (15). In this study,FOY-007
levels in the pancreas specimens in group C were 32
times those in group B. In comparisonwith individual
parts of the pancreas, FOY- 007 levels in the pancreatic
head were12 times higher. In the pancreatic body, that
in group C was46 times that in group B, which was
significantly higher than that in group B. Also, in the
pancreatic tail, that in the group C was 51 times that
in group B. In the intravenous infusion group, in each
part of the pancreas, FOY-007 levels were equal. In
the meantime, in the intraarterial infusion group, of
the body and tail of the pancreas and pancreas head,
pancreas body was had an especially high value, be-
cause in the intravenous infusiongroupFOY-007 flowed
in the systemic circulation and only slightly flowed in
the pancreas (16). Therefore, the intravenous infusion
group showed lowvalues compared to the intraarterial
infusion groupwhich flowed directly in the pancreas. In
the present experiment, the tip of intraarterial infusion
catheter was in the celiac trunk. In short it was con-
sidered that FOY-007 levels in the pancreas head had
decreased because of FOY-007 running off to the prop-
ria hepatic artery. The body and tail of the pancreas
showed high values because they were near the tip
of the catheter. Clinically, necrosis position and necrosis
range of the pancreas are determined by diagnostic
imaging. And the position and number of arterial cathe-
ters are examined for every case. The tip of the intraar-
terial infusion catheter is stored in the pancreatitis po-
sition, so it has a high value in the pancreas local field
for the drug. This suggests that intraarterial infusion
therapy can cure pancreatitis.
In the experimental examination of the infusion
method of a protease inhibitor, Takasugi et al .(6)
reported intraduodenal infusion of FOY-305 and FOY-
007 prevented acute pancreatitis in rats and dogs.
Wakayama et al. (7) reported intraductal administra-
tion of FOY-007 prevented acute pancreatitis in dogs.
The administration of a protease inhibitor to these
duct systems has no rational when considered in terms
of the mechanism of pancreatitis pathogenesis. How-
ever, a clinical method for administering a protease
inhibitor in pancreatic ducts has not been established
for severe acute pancreatitis. Therefore, only large
intravenous or intraarterial injection allow us to place
a protease inhibitor in the pancreas. At present, in
clinics, continuous arterial infusion therapy using FUT-
175 widely used, and amarked effecthasbeen reported.
In the past, it was generally known that this medicine
caused hyperkalemia due to an inhibitory effect of Na
and K-ATPase activity of renal tubules. Recently, the
secretion interference of Prostacin, a serine protease
which appears in uriniferous tubule epithelial cells,
was found to cause hyperkalemia ; in short, Prostacin
was normally adjusting the electrolyte balance by ac-
tivating the endothelial Na channel of distal renal tu-
bules. However, FUT-175 inhibited the secretion of
Prostacin, and suppressed the endothelial Na channel
activity, and possibly causing hyperkalemia (17). The
effectiveness of continuous arterial infusion of FOY-
007 that had an equal effect did not cause any electrolyte
abnormality. The usefulness of FOY-007 for acute pan-
creatitis from the results of amultiple facility random-
ized comparison test in Europe was not confirmed
(18). However, its usefulness in pancreatitis from the
results of recent metanalysis was demonstrated (19).
As a result, in the intraarterial infusion group, the amy-
lase and lipase values in serum and ascites, and the
pancreatic necrosis rate were significantly improved.
A significant improvement in the intravenous infusion
group in serum amylase and lipase values was noted.
However, there was no significance for amylase, lipase
values in ascites, or the pancreatic necrosis rate. Though
the dose used this timewas a quantity over 2mg/kg/hr
for which the safety had been confirmed in the clinical
analysis for DIC, the pancreatic necrosis depression
effect due to the intravenous infusionwas not sufficient.
This is probably because in the intravenous infusion,
a dilution effect due to blood occurs, and FOY-007 is
rapidly hydrolyzed by esterase which is abundant in
blood plasma (20). FOY-007 levels in specimens of the
pancreas in the intraarterial infusion group exceeded
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those in the intravenous infusion group by 32 times, and
the pancreatic necrosis was significantly suppressed.
In addition, the increase in FOY-007 levels in the pan-
creas was obtained by the intraarterial infusionmethod,
and an improvement in the pancreaticnecrosis ratewas
expected.
In conclusion, continuous arterial infusion of FOY-
007 markedly reduce inflammation of the pancreas in
an animal model of acute pancreatitis. We conclude
that this method is clinically applicable in acute pan-
creatitis.
REFERENCES
1. Cavallini G, DI FrancescoV,BovoP :Antiprotease :
new aspects of treatment. In : BuchlerMW,UhlW,
Friess H, eds. Acute pancreatitis. Novel concepts
in biology and therapy. Blackwell Science, Berlin,
1999, pp.299-305
2. Grozinger KH,SchreyA,WabnitzRW:Proteinase-
Inhibition. Dr.C.Wolf & Sohn, Munchen, 1981
3. Lankish PG,PohlU,GokeB,OttoJ,Wereszcynska-
Siemiatkowska U, Grone H-J, Rahlf G : Effect of
FOY-305(camostat) on severe acute pancreatitis
in two animal models. Gastroenterology 96 : 193-
199, 1989
4. Niederau C, Liddle RA, Ferrell LD, Grendell JH :
Benefical effects of cholecystokinin-receptorblock-
ade and inhibition of proteolytic enzyme activity
in experimental acute hemorrhagic pancreatitis
in mice. Gastroenterology 96 : 193-199, 1989
5. Wisner JR, Renner IG, Grendell JH, Niederau
C, Ferrell LD : Gabexatemesilate (FOY) protects
against ceruletide-induced acute pancreatitis in
the rat. Pancreas 2 : 181-186, 1987
6. Takasugi S, Yonezawa H, Ikei N, Kanno T: Pre-
vention of acute experimental pancreatitis in rats
and dogs by intraduodenal infusion of a synthetic
trypsin inhibitor. Digestion 24 : 36-41, 1982
7. Wakayama T, Itoh T, Shibayama K, Idezuki Y :
Prevention of the spread of experimental acute
pancreatitis by intraductal administration of a
synthetic protease inhibitor in dogs. Am J Gas-
troenterol 84 : 272-278, 1989
8. BradleyⅢEL,WarshawAL : Pancreatic Abscess.
The Pancreas : biology, pathobiology, and disease,
2nd ed, Go VLW, eds. Raven Press, New York,
1993, pp.643-663
9. TopazianM, Gorelick FS. Acute pancreatitis. In:
Yamada T, Alpers DH, Laine L, eds. Textbook of
Gastroenterology, Third Edition, Lippincott Wil-
liams &Wilkins, Philadelphia, 1999, pp.2121-2150
10. Steer ML : Pathogenesis of acute pancreatitis.
Digestion 58 (Suppl 1) : 46 -49, 1997
11. Leach SD, Modlin IM, Scheele GA, Gorelick FS :
Intracellular activation of digestive zymogens
in rat pancreatic acini. Stimulation by high dose
of cholecystokinin. J Clin Invest 87 : 362-366, 1991
12. Ogawa M:Mechanisms of the development of
organ failure following surgical insult : the‘second
attack’ theory. Clin Intens Care 7 : 1-5, 1996
13. Kaller H, Patzschke K, Wegner LA : Pharmacoki-
netic observations following intravenous admini-
stration of radioactively labelled aprotinin in vol-
unteers. Eur J DrugMetabol Pharmacokinet 3 :
79 -85, 1965
14. Takeda K,Matsuno S, SunamuraM,MiyagawaK,
Sato T: Effect of continuous intraarteial infusion
trypsin inhibitor on acute experimental pancrea-
titis in dogs. J Jpn Panc Soc 2 (in Japanese):151-
158, 1987
15. Kakugawa Y, TakedaK, SunamuraM, Kawaguchi
S, Kobari M, Matsuno S : Effect of continuous
arterial infusion of protease inhibitor on experi-
mental acute pancreatitis induced by closed duo-
denal loop obstraction. Jpn J Gastroenterol 87(in
Japanese) : 1444 -1450, 1990
16. Masayasu S, Tsumoru M, Hidetoshi Y:Studies
on Absorption, Distribution, Excretion andMe-
tabolism of Ethyl p-(6-guanidinohexanoyloxy)
benzoate methanesulfonate. Pharmacometrics
9 : 733 -742, 1975
17. Kenichirou K, Kimio T:Secretion mechanism of
the prostaglandin in the renal uriniferous tubule
and examination of the clinical significance. The
Kumamoto Univ. Medical School Third Medi-
cine : Sixth disease state and protease in the treat-
ment and inhibitor workshop. 2001 August 3 4
(in japanese).
18. Buchler M, Malferthiner P, UhlW, Scholmerich
J, Stockmann F, Adler G, GausW, Rolle K, Beger
HG : Gabexatemesilate in humanAcute pancrea-
titis. Gastroenterology 104 : 1165 -1170, 1993
19. Messori A, Rampazzo R, Scroccaro G, Olivato R,
Bassi C, Falconi M, Pederzoli P, Martini N : Ef-
fectiveness of gabexatemesilate in acute pancrea-
titis :a meta-analysis. Dig Dis Sci 40 : 734 -738,
1995
20. Nishijima MK, Takezawa J, TaenakaN, Shimada
Y, Yoshiya I : Application of HPLCmeasurement
of plasma concentration of gabexate mesilate.
Thromb Res 31 : 279-284, 1983
The Journal of Medical Investigation Vol. 51 August 2004 １９３
